Mutations reveal how tuberculosis enzyme recognizes substrates and intermediates

Tuberculosis remains a leading global killer, and the rise of drug-resistant strains has made finding new molecular targets urgent. One promising target in Mycobacterium tuberculosis (Mtb) is Methionyl-tRNA synthetase (MetRS), an enzyme that helps start and extend the process of building proteins inside the bacterium. To understand how MetRS works and how particular changes can break its function, Rukmankesh Mehra and colleagues undertook a focused study using detailed sequence analyses and computer-based experiments. They looked at MetRS in two key chemical situations: the substrate-bound state, when methionine and ATP are attached and ready to react, and an intermediate state, when the reaction product methionyl-AMP sits in the active site. The team did this not only for the normal, wild-type enzyme but also for three single-amino-acid mutants named H21A, K54A, and E130A. In total they set up eight systems — two wild-type and six mutant configurations — and ran molecular dynamics simulations adding up to 24 microseconds of simulated time. This approach let them compare how the enzyme behaves and binds chemicals in both normal and mutated forms, shedding light on why some mutations cause loss of activity.

The core of the study used molecular dynamics simulations to track the detailed motions and interactions of MetRS in its different chemical states. By simulating the substrate-bound form (methionine and ATP present) and the intermediate form (methionyl-AMP present) for both wild-type and mutant proteins, the researchers identified distinct patterns of stability and binding. Key results showed that the wild-type protein was more stable when bound to the substrate pair methionine and ATP than when holding the intermediate methionyl-AMP. Mutant proteins, in contrast, were less stable in the substrate state but gained stability in the intermediate state. From these differences the team inferred molecular reasons for the mutants’ loss of activity: the mutations increase instability in the substrate state and appear to disrupt the pyrophosphate-ATP exchange step by changing how the substrate interacts with the protein. Importantly, once methionyl-AMP is formed as the intermediate, these mutations have minimal or no further effect on the enzyme. The simulation findings align with available experimental data, reinforcing the conclusions.

These results provide a clear molecular picture of how Mtb MetRS distinguishes between the substrate pair methionine and ATP and the reaction intermediate methionyl-AMP. The discovery that the substrate state has a longer residence time and greater sensitivity to mutation, while the intermediate is short-lived and less affected by the same changes, explains why certain single-site mutations lead to loss of enzymatic activity. By establishing that disruption of substrate-protein interactions and interference with the pyrophosphate-ATP exchange underlie mutant instability, the study clarifies a mechanism that connects sequence changes to functional failure. For researchers focused on Mycobacterium tuberculosis, this work sharpens understanding of MetRS as a drug target and points to specific stages of the catalytic cycle — especially the substrate-bound state — that might be most vulnerable to intervention. Because the observations are consistent with experimental data, they provide a stronger foundation for future studies aimed at exploiting these mechanistic differences to combat drug-resistant tuberculosis.